Page 10 - DIAGEN

Hermatology primeFISH Products

HEMATOLOGY

PANEL

17-091 EV/1 (3q26.2) Breakapart

ınv(3)/t(3;3) and less commonly ins(3;3)(q26.2;q2lq26.2) therapy and poor clinical outcome. Chromosomal rear-
occur in l-2.5% of acute myeloid leukemia (AML) and rangements involving the 3q26.2 region are associated
occur in myelodysplastic syndromes and chronic it is with myeloid malignancies, abnormal expression of the
alsa observed in the blastic stage of myeloid leukemia. MECOM gene, an unfavorable prognosis, and an aggres-
Various other MECOM translocations involving other sive clinical course.
fusion partner genes have alsa been reported in various
types of myeloid malig nancies. 3q26.2 rearrangements
are associated with minimal or no response to chemo

İNV3

NORMAL

WI-4113 RH58597 SHGC-9113 SHGC-81191 D11S3226 RH78696
5' 3' 5' 3' 3' 5'
Gen Tel RED SEPERATED BLUE SEPERATED
GOLIM4 MECOM MYNN
470 kb 164 kb 234 kb

3q26.2

(Not to scale)

www.diagen.com.tr References
Arber DA, et al. (2016) Blood 127: 2391-405.
De Braekeleer E, et al. (2011) Anticancer Res 31: 3441-8.
Swerdlow et al., (eds,) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue, Lyon, France, 4th edition, IARC,2017
Mascarello JT, Hirsch B, Kearney HM, et al. Section E9 of the American College of Medical Genetics technical standards and guidelines:
fluorescence in situ hybridization. Genet Med. 2011;13(7):667-675.

10 PRODUCT CATALOGUE info@diagen.com.tr